Journal of Pain and Symptom Management
Volume 27, Issue 3 , Pages 191-194 , March 2004

Withdrawal symptoms during chronic transdermal fentanyl administration managed with oral methadone

References 

  1. Davies AN, Bond C. Transdermal fentanyl and the opioid withdrawal syndrome. Palliat Med. 1996;10:348
  2. Hunt R. Transdermal fentanyl and the opioid withdrawal syndrome. Palliat Med. 1996;10:347–348
  3. Higgs CMB, Vella-Bricant J. Withdrawal with transdermal fentanyl. J Pain Symptom Manage. 1995;10:4–5
  4. Gourlay GK. Treatment of cancer pain with transdermal fentanyl. Lancet Oncol. 2001;2:165–172
  5. Han PKJ, Arnold R, Bond G, et al.  Myoclonus secondary to withdrawal from transdermal fentanyl: a case report and literature review. J Pain Symptom Manage. 2002;23:66–72
  6. Burza M, Ginobbi P, Fusco G, et al.  La via transdermica come alternativa agli oppioidi per os nel dolore oncologico. Clin Ter. 1998;149:277–280
  7. Ripamonti C, Groff L, Brunelli C, et al.  Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?. J Clin Oncol. 1998;16:3216–3221
  8. Mercadante S, Casuccio A, Fulfaro F, et al.  Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol. 2001;19:2898–2904
  9. Portenoy RK, Southam MA, Gupta SK, et al.  Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics. Anesthesiol. 1993;78:36–43
  10. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids. Focus on transdermal fentanyl. Clin Pharmacokinet. 2000;38:59–89

PII: S0885-3924(03)00495-0

doi: 10.1016/j.jpainsymman.2003.12.003

Journal of Pain and Symptom Management
Volume 27, Issue 3 , Pages 191-194 , March 2004

Article Tools